A possible limitation of this study is that the effect of CHIP-carrying MSCs was only observed in vitro, and in vivo data to support to test its efficacy and effectiveness as a therapeutic strategy in clinical treatment against diabetes-induced damages is lacking. The gene discussed is STUB1; the disease is diabetes mellitus.